EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES (EEJMMS)
ISSN: 2992-4103
©EEJMMS Publications Volume 6 Issue 3 2025

The Gut Microbiome in Diabetes and Obesity: Mechanisms and Therapeutic Implications

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

ABSTRACT

Diabetes and obesity, two interrelated global health epidemics, are complex metabolic disorders influenced by genetic, environmental, and lifestyle factors. Recent evidence has illuminated the crucial role of the gut microbiome, a vast ecosystem of microorganisms inhabiting the gastrointestinal tract in the pathogenesis of these conditions. Dysbiosis, or imbalance in gut microbial composition, has been consistently linked to insulin resistance, low-grade chronic inflammation, impaired glucose metabolism, and altered energy homeostasis. This review explores the intricate mechanisms by which the gut microbiota influences the development and progression of diabetes and obesity, including modulation of gut barrier integrity, lipopolysaccharide-induced inflammation, short-chain fatty acid production, bile acid signaling, and interaction with the host immune system. We also highlight emerging therapeutic strategies targeting the gut microbiota, such as prebiotics, probiotics, synbiotics, fecal microbiota transplantation (FMT), and microbiome-modulating drugs. Understanding these microbial mechanisms opens new frontiers in personalized medicine for managing metabolic disorders. This review consolidates current knowledge and identifies future directions to harness the therapeutic potential of the gut microbiome in diabetes and obesity.

Keywords: Gut microbiome, diabetes, obesity, dysbiosis, insulin resistance, short-chain fatty acids

INTRODUCTION

Diabetes mellitus and obesity are among the most pressing global public health challenges of the 21st century, with prevalence rates continuing to rise at an alarming pace, especially in industrialized and rapidly urbanizing societies.[1–3] The World Health Organization (WHO) estimates that more than 500 million people are currently living with diabetes, and over 1.9 billion adults are classified as overweight or obese globally[4–6]. These metabolic disorders are associated with a host of comorbidities, including cardiovascular disease, renal dysfunction, neuropathy, and reduced life expectancy, making them leading contributors to the global burden of disease.

Traditionally, the etiology of diabetes and obesity has been attributed to a combination of genetic predisposition, poor dietary habits, sedentary lifestyles, and environmental exposures[7, 8]. However, growing scientific interest in recent years has turned to the gut microbiome as a pivotal player in the development and progression of metabolic diseases[9]. This interest has been spurred by advances in next-generation sequencing technologies and metagenomic analyses, which have provided unprecedented insight into the diversity, composition, and function of the gut microbial ecosystem[9]. The gut microbiome refers to the trillions of microorganisms residing in the gastrointestinal tract, including bacteria, archaea, viruses, fungi, and protozoa. These microorganisms engage in complex symbiotic interactions with the host, contributing to essential physiological processes such as digestion, nutrient absorption, bile acid metabolism, immune modulation, and the synthesis of vitamins and short-chain fatty acids (SCFAs)[10]. The composition of the gut microbiome is dynamic and influenced by multiple factors, including mode of birth delivery, diet, age, antibiotic use, and geographic location[10].

Emerging evidence suggests that disturbances in the gut microbiome collectively termed dysbiosis may have profound implications for metabolic health[11, 12]. Dysbiosis is characterized by a loss of microbial diversity, an overrepresentation of pathogenic bacteria, and a decline in beneficial commensals. Such imbalances have been linked to the pathogenesis of type 2 diabetes (T2D), type 1 diabetes (T1D), and obesity through a variety of mechanisms[13, 14]. These include increased intestinal permeability ("leaky gut"), systemic inflammation, altered energy harvest from the diet, insulin resistance, and disruption of signaling pathways involved in glucose and lipid metabolism[14].

In type 2 diabetes, for instance, gut microbial profiles are often marked by a reduction in butyrate-producing bacteria such as *Faecalibacterium prausnitzii*, which play a role in maintaining gut barrier integrity and reducing inflammation. Simultaneously, an enrichment of opportunistic pathogens may promote endotoxemia and metabolic endotoxemia, exacerbating insulin resistance[15]. In type 1 diabetes, an autoimmune condition, gut dysbiosis may contribute to the breakdown of immune tolerance and the initiation of autoimmunity against pancreatic β-cells. Obesity, too, has been associated with distinct alterations in microbial composition, such as an increased Firmicutes-to-Bacteroidetes ratio, which is thought to enhance energy extraction from the diet and promote fat deposition[15]. Given the intricate and bidirectional relationship between the gut microbiome and host metabolic health, there is growing interest in microbiome-targeted interventions as potential therapeutic strategies for diabetes and obesity. These strategies include the use of prebiotics, probiotics, synbiotics, fecal microbiota transplantation (FMT), and dietary modifications aimed at restoring a balanced microbial community. Understanding the underlying mechanisms by which the gut microbiota influences metabolic homeostasis is crucial for developing effective, personalized treatments for these chronic diseases[15]. This review aims to explore the current knowledge on the role of the gut microbiome in the development and management of diabetes and obesity, elucidating the underlying mechanisms and highlighting therapeutic implications. By understanding the complex interplay between host and microbiota, we can move closer to microbiome-based precision medicine in metabolic disease management.

Composition and Functions of the Gut Microbiome

The adult human gastrointestinal tract is home to an extraordinarily complex and dense microbial ecosystem, often referred to as the gut microbiota. This dynamic community consists of trillions of microorganisms, including bacteria, archaea, viruses, and fungi. Among the bacterial inhabitants, the phyla *Firmicutes* and *Bacteroidetes* dominate, comprising more than 90% of the gut microbial population. These microbial residents are not passive bystanders; rather, they play crucial roles in maintaining host health through a wide range of biochemical, immunological, and metabolic activities that contribute to the overall physiological homeostasis of the human body[16].

One of the most well-documented functions of the gut microbiota is the fermentation of indigestible dietary fibers, a complex carbohydrate that escape digestion in the upper gastrointestinal tract. Once these fibers reach the colon, they serve as substrates for microbial fermentation, leading to the production of short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate[17]. Each of these SCFAs exerts unique physiological effects. Butyrate, for example, serves as a primary energy source for colonocytes, promotes the integrity of the intestinal lining, and possesses anti-inflammatory properties. Propionate is absorbed into the bloodstream and transported to the liver, where it influences gluconeogenesis and satiety signaling[18]. Acetate, the most abundant SCFA, enters systemic circulation and is utilized in peripheral tissues, including muscle and adipose tissue, thereby participating in cholesterol metabolism and appetite regulation. Together, these metabolites not only provide energy but also modulate host metabolism, influence lipid and glucose homeostasis, and contribute to the prevention of metabolic disorders such as obesity and type 2 diabetes[18].

Beyond metabolic contributions, the gut microbiota plays an indispensable role in the regulation of the host immune system. From early life through adulthood, microbial exposure is essential for the maturation of both innate and adaptive immunity. The gut microbiota engages in a continuous crosstalk with the host's immune cells, facilitating immune tolerance to harmless antigens while enhancing the ability to mount effective responses against pathogenic organisms[19]. This immunomodulatory function involves complex signaling pathways, including the stimulation of pattern recognition receptors such as Toll-like receptors (TLRs) and the production of microbial metabolites that affect the activity of regulatory T cells (Tregs) and dendritic cells. SCFAs, particularly butyrate, enhance the differentiation of Tregs, which are essential for maintaining immune tolerance and suppressing inflammatory responses. Consequently, disruptions in the microbial composition, a condition known as dysbiosis, are often linked to the development of autoimmune and inflammatory diseases, including inflammatory bowel disease (IBD), allergies, and even neuroinflammatory conditions[19].

Another critical function of the gut microbiota is its role in maintaining the integrity of the intestinal barrier. The gut epithelium acts as a selective barrier that allows nutrient absorption while preventing the translocation of pathogens, toxins, and antigens into the systemic circulation[20]. Commensal microbes support this barrier through several mechanisms, including the stimulation of mucin production, strengthening of tight junction proteins, and inhibition of pathogenic bacterial colonization. For example, butyrate has been shown to upregulate the expression of tight junction proteins such as claudins and occludins, reinforcing epithelial integrity and reducing intestinal permeability often referred to as "leaky gut." When this barrier function is compromised, it can lead to systemic inflammation and has been implicated in a variety of chronic diseases, including metabolic syndrome, cardiovascular disease, and neurological disorders[21].

In addition to fermentation and immune regulation, the gut microbiota is heavily involved in bile acid metabolism, a process that significantly influences lipid and glucose homeostasis. Primary bile acids are synthesized in the liver from cholesterol and secreted into the intestine, where they aid in the digestion and absorption of dietary fats[22]. Gut microbes subsequently convert these primary bile acids into secondary bile

acids through enzymatic deconjugation and dehydroxylation processes. These secondary bile acids function as signaling molecules that interact with host receptors such as the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor (TGR5). Activation of these receptors influences various metabolic pathways, including those involved in lipid synthesis, glucose metabolism, and energy expenditure[23]. Thus, the microbiota-mediated modification of bile acids represents a key mechanism by which gut microbes can exert systemic effects on host metabolism and contribute to the development or prevention of metabolic disorders[23].

In sum, the gut microbiota performs an array of vital functions that are essential for human health. Through the fermentation of dietary fibers into SCFAs, modulation of immune responses, reinforcement of the gut barrier, and regulation of bile acid metabolism, this microbial community plays a central role in metabolic, immune, and gastrointestinal homeostasis. An imbalance in this finely tuned ecosystem can have profound implications, underscoring the importance of maintaining a healthy gut microbiome through diet, lifestyle, and, when necessary, therapeutic interventions.

Gut Microbiome and Obesity

Microbiota Composition in Obesity

The composition of the gut microbiota plays a significant role in the development and progression of obesity. Numerous studies have consistently shown that obese individuals tend to have a distinctive microbial signature when compared to lean individuals. One of the most notable observations is an increased Firmicutes-to-Bacteroidetes ratio. This shift is thought to favor the extraction of energy from the diet, thereby contributing to excessive caloric availability[24]. In addition, obesity is often associated with a reduction in overall microbial diversity, a hallmark of dysbiosis. A diverse gut microbiome is generally considered beneficial, as it reflects a more resilient and functionally stable microbial community. Reduced diversity in obese individuals suggests a loss of important microbial functions and ecological niches, potentially leading to imbalances that promote metabolic dysfunction[24].

Moreover, specific microbial taxa known to confer metabolic benefits are often depleted in obesity. For example, *Akkermansia muciniphila*, a mucin-degrading bacterium associated with improved gut barrier function and anti-inflammatory effects, is typically found in lower abundance in obese individuals[25]. The depletion of *Akkermansia* may contribute to increased gut permeability and systemic inflammation, two processes commonly linked to obesity-related metabolic disorders. Similarly, levels of *Bifidobacterium* species, known for their probiotic effects and ability to modulate immune responses, are also reduced in obesity. These bacteria help maintain intestinal integrity and produce metabolites that influence host metabolism favorably. Their decreased presence further underscores the compromised metabolic environment in obese individuals[25].

The changes in microbiota composition observed in obesity are influenced by a range of factors, including diet, genetics, lifestyle, and environmental exposures. Diet, particularly the consumption of high-fat and low-fiber foods, is a major modulator of microbial structure. Such dietary patterns promote the growth of bacteria that may encourage energy storage, low-grade inflammation, and insulin resistance[25]. Furthermore, the gut microbiota in obesity is often less responsive to dietary interventions, potentially hindering weight loss efforts[26]. Understanding the complex relationships between microbiota composition and obesity may provide new insights into therapeutic strategies. Interventions such as prebiotics, probiotics, dietary modification, and even fecal microbiota transplantation are being explored as ways to restore a healthy gut microbial balance and combat obesity-related metabolic impairments.

Mechanistic Insights

The gut microbiota contributes to obesity through several interrelated mechanisms that involve energy regulation, metabolic signaling, and inflammation[27]. One of the key pathways is enhanced energy harvesting from the diet. Gut microbes possess a diverse array of enzymes capable of breaking down complex polysaccharides that are otherwise indigestible by human enzymes[27]. These polysaccharides are fermented into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which serve as additional energy sources. The increased production and absorption of these microbial metabolites provide more calories to the host, potentially leading to a positive energy balance and weight gain over time. This enhanced energy extraction is particularly pronounced in microbiota dominated by Firmicutes, which are efficient fermenters.

While SCFAs generally have beneficial roles in regulating gut health, inflammation, and satiety, excessive SCFA production in the context of obesity may contribute to metabolic disturbances. Specifically, acetate and butyrate have been shown to stimulate lipogenesis in the liver, increasing fat deposition. Moreover, acetate may act as a substrate for cholesterol and fatty acid synthesis, further promoting adiposity. Thus, although SCFAs are essential for maintaining colonic health and energy homeostasis, their overproduction in an obese microbiome can paradoxically facilitate fat accumulation[28].

Another critical mechanism is the development of metabolic endotoxemia, which is largely influenced by dietary patterns. High-fat diets can disrupt gut barrier function by altering the expression of tight junction proteins, increasing intestinal permeability. This compromised barrier allows bacterial components such as lipopolysaccharides (LPS) from gram-negative bacteria to translocate into the systemic circulation. Circulating

LPS is recognized by the immune system as a danger signal and can trigger low-grade, chronic inflammation through the activation of Toll-like receptor 4 (TLR4)[29]. This inflammatory state is a major driver of insulin resistance and other metabolic derangements seen in obesity.

These microbiota-mediated mechanisms underscore the dynamic interplay between the gut and host metabolism. They illustrate how microbial activities extend beyond digestion and profoundly influence energy storage, immune responses, and systemic metabolic outcomes. Unraveling these mechanisms not only deepens our understanding of obesity pathophysiology but also opens new avenues for therapeutic targeting of the gut microbiome. Strategies such as dietary modulation, selective microbiota enrichment, and anti-inflammatory interventions hold promise in mitigating the impact of gut-derived signals on obesity and its associated complications.

Gut Microbiome and Diabetes

Type 2 Diabetes (T2D)

Type 2 diabetes (T2D) is a complex metabolic disorder primarily marked by chronic hyperglycemia, which results from a combination of insulin resistance and progressive β-cell dysfunction[1, 30, 31]. The gut microbiota has emerged as a significant modulator in T2D pathogenesis. Patients with T2D often exhibit a state of gut dysbiosis, characterized by decreased microbial diversity and specific compositional shifts. One notable alteration is the reduced abundance of *Faecalibacterium prausnitzii*, a prominent butyrate-producing bacterium known for its anti-inflammatory properties and role in maintaining gut barrier integrity. At the same time, there is often an increase in opportunistic and potentially pro-inflammatory bacterial taxa such as *Ruminococcus gnavus* and *Bacteroides*[13, 14]. These microbial imbalances contribute to a systemic pro-inflammatory environment and can exacerbate insulin resistance. Furthermore, altered microbial metabolism in T2D affects the production of short-chain fatty acids (SCFAs) and branched-chain amino acids (BCAAs), both of which are critical in energy metabolism and insulin signaling. The gut-liver axis also becomes impaired, leading to dysregulated bile acid signaling and increased endotoxemia. Together, these changes suggest that targeting the gut microbiome may offer a promising therapeutic avenue for T2D prevention and management[32].

Type 1 Diabetes (T1D)

Type 1 diabetes (T1D) is an autoimmune condition characterized by the destruction of pancreatic β-cells, leading to absolute insulin deficiency. While the genetic predisposition plays a critical role in T1D, environmental factors, especially gut microbiota alterations, are increasingly recognized as crucial in disease onset and progression[33]. Studies have shown that children at risk for T1D often exhibit early-life microbial dysbiosis marked by reduced bacterial diversity and a lower abundance of beneficial SCFA-producing bacteria such as *Bifidobacterium* and *Akkermansia*. These beneficial microbes are known for their role in regulating gut barrier function, maintaining immune homeostasis, and suppressing inflammation[34]. A compromised gut barrier due to decreased SCFA levels can lead to increased intestinal permeability or "leaky gut," allowing microbial antigens and endotoxins to enter circulation and trigger systemic immune responses. This heightened immune activity may contribute to the breakdown of self-tolerance and the activation of autoreactive T cells against pancreatic β-cells. Additionally, the timing of microbiota shifts, especially during critical windows of immune development in early childhood, appears to influence the trajectory toward autoimmunity[35]. Understanding these microbiota-host interactions opens up potential for microbiome-based interventions as preventive strategies in high-risk individuals.

Key Mechanisms

Several interrelated mechanisms link gut microbiota alterations to the development and progression of diabetes. One central mechanism is gut barrier dysfunction. In both T1D and T2D, increased intestinal permeability often referred to as "leaky gut" permits the translocation of microbial antigens, endotoxins, and other inflammatory stimuli into the bloodstream. This promotes systemic immune activation and low-grade inflammation, which contributes to insulin resistance and autoimmunity. Another crucial mechanism involves immune modulation[36]. The gut microbiota plays a key role in shaping immune responses by influencing T cell differentiation. In the context of diabetes, altered microbial antigen presentation and SCFA deficiencies can skew immune responses toward pro-inflammatory T helper 1 (Th1) and Th17 phenotypes, exacerbating immune-mediated β-cell destruction in T1D and insulin resistance in T2D. Additionally, bile acid metabolism is significantly influenced by the gut microbiota. Secondary bile acids, produced by microbial enzymes, can bind to host receptors such as farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5)[37]. Activation of these receptors affects glucose and lipid metabolism, energy expenditure, and insulin sensitivity. Dysbiosis disrupts this bile acid signaling axis, further impairing metabolic homeostasis. Collectively, these mechanisms highlight the gut microbiota as a critical interface in the pathophysiology of diabetes[37].

Therapeutic Implications

Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Specific strains such as *Lactobacillus* and *Bifidobacterium* have been shown to improve metabolic health,

particularly in individuals with obesity and diabetes.[38] Clinical trials demonstrate that probiotic supplementation can enhance insulin sensitivity, reduce systemic inflammation, and improve lipid profiles by restoring gut microbial balance[39]. These effects are largely mediated through modulation of gut permeability, reduction of pro-inflammatory cytokines, and increased production of beneficial short-chain fatty acids (SCFAs). Continued research is uncovering strain-specific effects and optimal dosing strategies for metabolic disease management.[39]

Prebiotics and Synbiotics

Prebiotics are non-digestible food components such as inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) that selectively stimulate the growth and activity of beneficial gut bacteria. Their fermentation by the gut microbiota leads to the production of SCFAs, which play crucial roles in energy metabolism, inflammation control, and gut barrier integrity[40]. Synbiotics, which combine probiotics and prebiotics, offer synergistic benefits by enhancing the survival and colonization of beneficial microbes while simultaneously fueling their activity. Together, these compounds have been associated with improved glucose homeostasis, lipid metabolism, and immune modulation in individuals with obesity or type 2 diabetes, making them valuable tools for metabolic intervention[40].

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation (FMT) involves the transfer of stool containing a complex microbial community from a healthy donor to the gastrointestinal tract of a recipient. Initially successful in treating recurrent *Clostridioides difficile* infections, FMT has recently shown promise in metabolic disease contexts[41]. Early clinical studies report that FMT from lean, healthy donors to individuals with metabolic syndrome can transiently improve insulin sensitivity and reduce markers of systemic inflammation[41]. The beneficial effects are thought to stem from restored microbial diversity and functional shifts in metabolite production, including SCFAs and bile acids. However, long-term efficacy and safety require further investigation.

Microbiome-Modulating Drugs

Microbiome-modulating drugs represent a new frontier in precision medicine, targeting microbial pathways that influence host metabolism. These therapeutics are designed to selectively enhance or inhibit specific microbial functions, such as short-chain fatty acid production, lipopolysaccharide (LPS) biosynthesis, and bile acid transformation[42]. For example, drugs that promote SCFA synthesis may improve insulin sensitivity and reduce inflammation, while inhibitors of LPS production could attenuate metabolic endotoxemia. Some agents also modulate gut-brain signaling pathways involved in appetite regulation[43]. Unlike broad-spectrum antibiotics, these drugs offer targeted intervention without disrupting overall microbial balance. They hold great promise for treating diabetes and obesity with minimal side effects.

Diet and Lifestyle

Diet and lifestyle choices are among the most powerful modulators of the gut microbiome. Diets rich in fiber, polyphenols, and plant-based components such as the Mediterranean diet foster microbial diversity and the abundance of beneficial taxa like *Akkermansia muciniphila* and *Bifidobacterium*[44]. These bacteria contribute to enhanced SCFA production, improved gut barrier integrity, and reduced systemic inflammation. Conversely, high-fat, low-fiber Western diets promote dysbiosis and metabolic dysfunction. Physical activity also supports a healthier microbiome by enhancing microbial richness and metabolic resilience. Sustainable dietary and lifestyle interventions not only shift microbial composition favorably but also help in long-term management of obesity and diabetes[44].

Future Perspectives

Although microbiome-based therapies show great promise, challenges remain, including inter-individual variability, regulatory hurdles, and long-term safety. Integrating multi-omics approaches—metagenomics, metabolomics, and transcriptomics—will enable more precise characterization of microbiome–host interactions. Personalized nutrition and targeted microbial interventions represent the frontier of metabolic disease management.

CONCLUSION

The gut microbiome is a central player in the pathogenesis and potential treatment of diabetes and obesity. Mechanistic insights into microbial regulation of host metabolism have paved the way for innovative therapeutic strategies. A deeper understanding of microbial ecology, host genetics, and environmental influences will be critical to fully harness the microbiome's therapeutic potential in combating metabolic diseases.

REFERENCES

1. Chandrasekaran, P., Weiskirchen, R.: The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. International Journal of Molecular Sciences. 25, 1882 (2024). https://doi.org/10.3390/ijms25031882
2. Chellappan, D.K., Chellian, J., Rahmah, N.S.N., Gan, W.J., Banerjee, P., Sanyal, S., Banerjee, P., Ghosh, N., Guith, T., Das, A., Gupta, G., Singh, S.K., Dua, K., Kunnath, A.P., Norhashim, N.A., Ong, K.H., Palaniveloo, K.: Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources. DMSO. 16, 2187–2223 (2023). https://doi.org/10.2147/DMSO.S390741

3. Chen, B., Li, T., Wu, Y., Song, L., Wang, Y., Bian, Y., Qiu, Y., Yang, Z.: Lipotoxicity: A New Perspective in Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 18, 1223–1237 (2025). https://doi.org/10.2147/DMSO.S511436
4. Ahmed, B., Konje, J.C.: The epidemiology of obesity in reproduction. Best Practice & Research Clinical Obstetrics & Gynaecology. 89, 102342 (2023). https://doi.org/10.1016/j.bpobgyn.2023.102342
5. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
6. Atangwho, I.J., Omang, W.A., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
7. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obesity Medicine. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
8. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obesity Medicine. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
9. Edeh, F.O., Ainebyoona, C., Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov Oncol. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
10. Pickard, J.M., Zeng, M.Y., Caruso, R., Núñez, G.: Gut Microbiota: Role in Pathogen Colonization, Immune Responses and Inflammatory Disease. Immunol Rev. 279, 70–89 (2017). https://doi.org/10.1111/imr.12567
11. Fujita, K., Matsushita, M., De Velasco, M.A., Hatano, K., Minami, T., Nonomura, N., Uemura, H.: The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome. Cancers (Basel). 15, 1375 (2023). https://doi.org/10.3390/cancers15051375
12. Kho, Z.Y., Lal, S.K.: The Human Gut Microbiome – A Potential Controller of Wellness and Disease. Front. Microbiol. 9, (2018). https://doi.org/10.3389/fmicb.2018.01835
13. Dahiya, D., Nigam, P.S.: Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. Int J Mol Sci. 24, 3074 (2023). https://doi.org/10.3390/ijms24043074
14. Fakharian, F., Thirugnanam, S., Welsh, D.A., Kim, W.-K., Rappaport, J., Bittinger, K., Rout, N.: The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis. Microorganisms. 11, 1849 (2023). https://doi.org/10.3390/microorganisms11071849
15. Craciun, C.-I., Neag, M.-A., Catinean, A., Mitre, A.-O., Rusu, A., Bala, C., Roman, G., Buzoianu, A.-D., Muntean, D.-M., Craciun, A.-E.: The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus. Biomedicines. 10, 308 (2022). https://doi.org/10.3390/biomedicines10020308
16. Aggarwal, N., Kitano, S., Puah, G.R.Y., Kittelmann, S., Hwang, I.Y., Chang, M.W.: Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chem Rev. 123, 31–72 (2022). https://doi.org/10.1021/acs.chemrev.2c00431
17. Morrison, D.J., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016). https://doi.org/10.1080/19490976.2015.1134082
18. Nogal, A., Valdes, A.M., Menni, C.: The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. 13, 1897212. https://doi.org/10.1080/19490976.2021.1897212
19. Zhao, Q., Elson, C.O.: Adaptive immune education by gut microbiota antigens. Immunology. 154, 28–37 (2018). https://doi.org/10.1111/imm.12896
20. Gieryńska, M., Szulc-Dąbrowska, L., Struzik, J., Mielcarska, M.B., Gregorczyk-Zboroch, K.P.: Integrity of the Intestinal Barrier: The Involvement of Epithelial Cells and Microbiota—A Mutual Relationship. Animals (Basel). 12, 145 (2022). https://doi.org/10.3390/ani12020145
21. Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L.R., Scaldaferri, F.: Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 19, 275–293 (2024). https://doi.org/10.1007/s11739-023-03374-w
22. Rowland, I., Gibson, G., Heinken, A., Scott, K., Swann, J., Thiele, I., Tuohy, K.: Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 57, 1–24 (2018). https://doi.org/10.1007/s00394-017-1445-8
23. Guzior, D.V., Quinn, R.A.: Review: microbial transformations of human bile acids. Microbiome. 9, 140 (2021). https://doi.org/10.1186/s40168-021-01101-1

24. Enache, R.-M., Profir, M., Roşu, O.A., Creţoiu, S.M., Gaspar, B.S.: The Role of Gut Microbiota in the Onset and Progression of Obesity and Associated Comorbidities. Int J Mol Sci. 25, 12321 (2024). https://doi.org/10.3390/ijms252212321
25. Zhao, Y., Yang, H., Wu, P., Yang, S., Xue, W., Xu, B., Zhang, S., Tang, B., Xu, D.: Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders. Virulence. 15, 2375555. https://doi.org/10.1080/21505594.2024.2375555
26. Conlon, M.A., Bird, A.R.: The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients. 7, 17 (2014). https://doi.org/10.3390/nu7010017
27. Geng, J., Ni, Q., Sun, W., Li, L., Feng, X.: The links between gut microbiota and obesity and obesity related diseases. Biomedicine & Pharmacotherapy. 147, 112678 (2022). https://doi.org/10.1016/j.biopha.2022.112678
28. Xiong, R.-G., Zhou, D.-D., Wu, S.-X., Huang, S.-Y., Saimaiti, A., Yang, Z.-J., Shang, A., Zhao, C.-N., Gan, R.-Y., Li, H.-B.: Health Benefits and Side Effects of Short-Chain Fatty Acids. Foods. 11, 2863 (2022). https://doi.org/10.3390/foods11182863
29. Park, J.-E., Park, H.-Y., Kim, Y.-S., Park, M.: The Role of Diet, Additives, and Antibiotics in Metabolic Endotoxemia and Chronic Diseases. Metabolites. 14, 704 (2024). https://doi.org/10.3390/metabo14120704
30. Arnesen, E.K., Thorisdottir, B., Bärebring, L., Söderlund, F., Nwaru, B.I., Spielau, U., Dierkes, J., Ramel, A., Lamberg-Allardt, C., Åkesson, A.: Nuts and seeds consumption and risk of cardiovascular disease, type 2 diabetes and their risk factors: a systematic review and meta-analysis. Food Nutr Res. 67, 10.29219/fnr.v67.8961 (2023). https://doi.org/10.29219/fnr.v67.8961
31. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Natural Product Communications. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
32. Hsu, C., Schnabl, B.: The gut–liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 21, 719–733 (2023). https://doi.org/10.1038/s41579-023-00904-3
33. Lucier, J., Mathias, P.M.: Type 1 Diabetes. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
34. Roy, S., Pokharel, P., Piganelli, J.D.: Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes. Mol Metab. 88, 101998 (2024). https://doi.org/10.1016/j.molmet.2024.101998
35. Shemtov, S.J., Emani, R., Bielska, O., Covarrubias, A.J., Verdin, E., Andersen, J.K., Winer, D.A.: The intestinal immune system and gut barrier function in obesity and aging. FEBS J. 290, 4163–4186 (2023). https://doi.org/10.1111/febs.16558
36. Li, X., Atkinson, M.A.: The Role for Gut Permeability in the Pathogenesis of Type 1 Diabetes – A Solid or Leaky Concept? Pediatr Diabetes. 16, 485–492 (2015). https://doi.org/10.1111/pedi.12305
37. Majumdar, S., Lin, Y., Bettini, M.L.: Host-microbiota interactions shaping T-cell response and tolerance in type 1 diabetes. Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.974178
38. Latif, A., Shehzad, A., Niazi, S., Zahid, A., Ashraf, W., Iqbal, M.W., Rehman, A., Riaz, T., Aadil, R.M., Khan, I.M., Özogul, F., Rocha, J.M., Esatbeyoglu, T., Korma, S.A.: Probiotics: mechanism of action, health benefits and their application in food industries. Front Microbiol. 14, 1216674 (2023). https://doi.org/10.3389/fmicb.2023.1216674
39. Salles, B.I.M., Cioffi, D., Ferreira, S.R.G.: Probiotics supplementation and insulin resistance: a systematic review. Diabetol Metab Syndr. 12, 98 (2020). https://doi.org/10.1186/s13098-020-00603-6
40. Ali, S., Hamayun, M., Siraj, M., Khan, S.A., Kim, H.-Y., Lee, B.: Recent advances in prebiotics: Classification, mechanisms, and health applications. Future Foods. 12, 100680 (2025). https://doi.org/10.1016/j.fufo.2025.100680
41. Yadegar, A., Pakpoor, S., Ibrahim, F.F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A.M., Wong, K., Monaghan, T.M., Kao, D.: Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe. 31, 695–711 (2023). https://doi.org/10.1016/j.chom.2023.03.019
42. Schupack, D.A., Mars, R.A.T., Voelker, D.H., Abeykoon, J.P., Kashyap, P.C.: The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 19, 7–25 (2022). https://doi.org/10.1038/s41575-021-00499-1
43. Akhtar, M., Chen, Y., Ma, Z., Zhang, X., Shi, D., Khan, J.A., Liu, H.: Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim Nutr. 8, 350–360 (2021). https://doi.org/10.1016/j.aninu.2021.11.005
44. Perrone, P., D'Angelo, S.: Gut Microbiota Modulation Through Mediterranean Diet Foods: Implications for Human Health. Nutrients. 17, 948 (2025). https://doi.org/10.3390/nu17060948

CITE AS: Bwanbale Geoffrey David (2025). The Gut Microbiome in Diabetes and Obesity: Mechanisms and Therapeutic Implications. EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES, 6(3):44-51